Destiny Pharma PLC (AIM:DEST) chief executive Neil Clark joined Proactive's Stephen Gunnion to share positive results from a preclinical study with its novel XF-73 dermal formulation, clearing the way for the second and final study of the product.
Clark telling Proactive that XF-73 is aimed at meeting a clear clinical need in a large market where peak product sales could reach half a billion US dollars.